Search the Newsreel

BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Misses Revenue Estimates

BioXcel Therapeutics (BTAI) reported a Q2 loss of $0.49 per share, beating the Zacks Consensus Estimate of a $0.51 loss, but missed revenue estimates with $0.18 million, 46.47% below consensus. Despite an earnings surprise this quarter and last, the company's shares have fallen 33.8% …

BioXcel Therapeutics (BTAI) flags going concern risk with high debt and cash strain

BioXcel Deadline Alert

Faruqi & Faruqi, LLP is investigating potential claims against BioXcel Therapeutics, Inc. (NASDAQ: BTAI) and reminds investors of the September 5, 2023, deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit stems from allegations that BioXcel made …

BioXcel Therapeutics Amends Oaktree Credit Pact, Extends Deal Deadline and Lowers Liquidity Floor

BioXcel Therapeutics has amended its credit agreement with Oaktree, extending the deadline to secure refinancing or alternative capital to August 21, 2026. The amendment also reduces the minimum liquidity covenant from $6.25 million to $3.0 million, providing the company with more time and financial …

BioXcel Therapeutics (BTAI) cuts liquidity covenant, faces August 2026 refinancing deadline

BioXcel Therapeutics (BTAI) has amended its Credit Agreement, extending its refinancing deadline to August 21, 2026, and reducing its minimum liquidity covenant from $6.25 million to $3.0 million. This amendment gives the company more time to secure financing or strategic options and eases its …

BTAI News | BIOXCEL THERAPEUTICS INC (NASDAQ:BTAI)

BTAI Q2'26 Earnings: EPS estimate is (0.44) USD

BioXcel Therapeutics, Inc. (BTAI) is expected to announce its Q2'26 earnings on August 11, with an estimated revenue of 484.63 thousand USD and an EPS of (0.44) USD. The article provides a table of historical and estimated revenue and EPS figures, along with surprise …

BioXcel Therapeutics Inc (BTAI) Earnings Forecast: Future EPS & Revenue Growth Estimates

BioXcel Shareholder Notice

Faruqi & Faruqi, LLP is investigating potential claims against BioXcel Therapeutics, Inc. (NASDAQ: BTAI) and encourages investors who lost over $100,000 to contact them before the September 5, 2023 deadline to seek lead plaintiff status. This investigation follows a significant stock drop after BioXcel …

BioXcel Therapeutics amends Oaktree-led credit agreement, defers loan payment to Aug. 31

BioXcel Therapeutics has amended its credit agreement with lenders led by Oaktree Fund Administration, deferring a loan payment of $9.02 million from July 31 to August 31, 2026. The company also saw its minimum liquidity covenant lowered to $6.25 million from $7.5 million. BioXcel …

BioXcel Therapeutics Wins Deferral on $9.0M Payment, Liquidity Covenant Cut to $6.25M Under Oaktree Deal

BioXcel Therapeutics (BTAI) has secured a deferral on a $9.0 million principal and interest payment with Oaktree until August 31, 2026, via the Eleventh Amendment to its Credit Agreement. This amendment also reduces the minimum liquidity covenant to $6.25 million. By August 10, 2026, …

BioXcel Shareholder Action Reminder

Faruqi & Faruqi, LLP is investigating potential claims against BioXcel Therapeutics, Inc. (NASDAQ: BTAI) and reminds investors of the September 5, 2023 deadline to seek the role of lead plaintiff in a federal securities class action. This action follows BioXcel's disclosure that a principal …

BioXcel Therapeutics Inc (BTAI) Institutional Confidence

This article from TradingKey provides an overview of BioXcel Therapeutics Inc (BTAI)'s institutional confidence, based on an updated score of 3.00 as of July 28, 2026. It details the shares held by various institutional investors and Star Investors, along with the percentage change in …

BioXcel Therapeutics Inc (BTAI) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of BioXcel Therapeutics Inc (BTAI), highlighting its current valuation score of 8.84 within the Pharmaceuticals industry. It also details the company's P/E ratio, noting that other relevant financial data such as P/B, P/S, and P/CF have not yet …

BTAI|BioXcel Therapeutics Inc|Price:0.845|Chg%:-0.022

This article provides a comprehensive stock analysis of BioXcel Therapeutics Inc (BTAI), highlighting its relatively stable fundamentals, high growth potential, and fair valuation within the Pharmaceuticals industry. The company is actively developing neuroscience and immuno-oncology candidates, with analysts predominantly rating it as a "Buy" …

BioXcel Therapeutics Inc (BTAI) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of BioXcel Therapeutics Inc's (BTAI) dividend and stock split history. It notes that the company has not distributed any dividends over the past five years. The article also details several merger-related stock splits scheduled for February 6, 2025, each …

BioXcel Therapeutics Inc (BTAI) Income Statement

This article provides an income statement for BioXcel Therapeutics Inc (BTAI), presenting detailed quarterly and annual financial data spanning several years. It includes key metrics such as total revenue, operating expenses, R&D expenses, operating profit, and net income, alongside basic and diluted earnings per …

BioXcel Therapeutics, Inc. Revenue Breakdown – MUN:BX20

BioXcel Therapeutics, Inc. (MUN:BX20) generated 546.61K EUR in revenue last year, primarily from its Medicines segment, a decrease from 2.19M EUR in the previous year. The United States was the company's largest contributor to revenue, accounting for the entire 546.61K EUR.

Al-Babtain Power & Telecommunication Co. Revenue Breakdown – TADAWUL:2320

BTAI|BioXcel Therapeutics Inc|Price:0.870|Chg%:+0.022

BioXcel Therapeutics Inc (BTAI) is a biopharmaceutical company utilizing AI to develop neuroscience and immuno-oncology medicines. Despite a recent weak stock market performance, the company's fundamentals are stable, growth potential is high, and institutional ownership is very high. Analysts have rated BTAI as a …

BioXcel Therapeutics (BTAI) Investor update Summary

BioXcel Therapeutics (BTAI) is preparing for the potential Q1 2027 launch of IGALMI for at-home treatment of acute agitation, targeting a significant market with no currently FDA-approved competitors. The company highlights high unmet need, strong physician and patient interest, and a favorable payer outlook …

BioXcel Therapeutics (BTAI) Q1 2026 earnings summary

BioXcel Therapeutics reported a net loss of $12.7 million for Q1 2026, an increase from Q1 2025, despite a slight rise in IGALMI® sales. The company achieved a significant regulatory milestone with FDA acceptance of its sNDA for IGALMI® for at-home use. However, BioXcel …

BTAI Forecast — Price Target — Prediction for 2027

What Makes BioXcel Therapeutics (BTAI) a New Buy Stock

BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates

BioXcel Therapeutics, Inc. (BTAI) Expected to Beat Earnings Estimates: Should You Buy?

BioXcel says at-home agitation drug could target 86M yearly episodes

BioXcel Therapeutics Stock Soars Amid New Drug Approval Speculation

What Analysts Think Is Changing The Story For BioXcel Therapeutics Now

BioXcel Therapeutics Stock Soars Amid Positive Clinical and Patent Developments

BioXcel Therapeutics, Inc. Share Price Live Today – NASDAQ:BTAI Stock Price, Chart, News, History

Bioxcel Therapeutics (BTAI) Stock Price, News & Analysis

BioXcel Therapeutics Soars: Analyzing Sustained Gains